ATE420112T1 - Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1 - Google Patents

Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1

Info

Publication number
ATE420112T1
ATE420112T1 AT99933205T AT99933205T ATE420112T1 AT E420112 T1 ATE420112 T1 AT E420112T1 AT 99933205 T AT99933205 T AT 99933205T AT 99933205 T AT99933205 T AT 99933205T AT E420112 T1 ATE420112 T1 AT E420112T1
Authority
AT
Austria
Prior art keywords
gene product
cancer antigens
tumor suppressive
antigens based
suppressive gene
Prior art date
Application number
AT99933205T
Other languages
English (en)
Inventor
Haruo Sugiyama
Yoshihiro Oka
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16714530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE420112(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Application granted granted Critical
Publication of ATE420112T1 publication Critical patent/ATE420112T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99933205T 1998-07-31 1999-07-30 Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1 ATE420112T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21809398 1998-07-31

Publications (1)

Publication Number Publication Date
ATE420112T1 true ATE420112T1 (de) 2009-01-15

Family

ID=16714530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99933205T ATE420112T1 (de) 1998-07-31 1999-07-30 Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1

Country Status (15)

Country Link
US (7) US7030212B1 (de)
EP (3) EP1103564B1 (de)
JP (2) JP4422903B2 (de)
KR (1) KR100767554B1 (de)
CN (4) CN102198266A (de)
AT (1) ATE420112T1 (de)
AU (1) AU4932199A (de)
BR (1) BRPI9912663B8 (de)
CA (1) CA2337743C (de)
DE (1) DE69940264D1 (de)
DK (1) DK1103564T3 (de)
ES (1) ES2318898T3 (de)
HK (1) HK1038929B (de)
PT (1) PT1103564E (de)
WO (1) WO2000006602A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
AR021849A1 (es) * 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
EP1371664B1 (de) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti-modifiziertes peptid
ATE494905T1 (de) * 2001-06-29 2011-01-15 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JP5230891B2 (ja) 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的ｔ細胞の新規な誘導方法
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ES2331305T3 (es) 2002-09-20 2009-12-29 International Institute Of Cancer Immunology, Inc. Peptidos de wt1 de tipo sustituido.
ES2332590T3 (es) * 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
WO2005001117A1 (ja) 2003-06-27 2005-01-06 Haruo Sugiyama Ｗｔ１ワクチン適応患者の選択方法
KR101213015B1 (ko) * 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
PT1731605E (pt) * 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
EP1951281B1 (de) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla klasse ii-bindungspeptide und diese umfassende zusammensetzungen und verfahren
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
WO2007120673A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
GB2440528A (en) * 2006-07-27 2008-02-06 Ist Superiore Sanita Antigen-antibody complexes
KR101323540B1 (ko) 2007-02-07 2013-10-29 사이단호진한다이비세이부쯔뵤우겐큐우카이 암의 치료제
BRPI0808084A2 (pt) 2007-02-27 2014-07-22 Int Inst Cancer Immunology Inc Método para ativação de células t auxiliadoras e composição para uso no método.
KR101773690B1 (ko) 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
CA2940962C (en) * 2007-12-05 2018-07-24 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
KR20140009168A (ko) 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
CA2839663A1 (en) 2011-06-28 2013-01-03 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
WO2013089252A1 (ja) 2011-12-14 2013-06-20 国立大学法人 高知大学 ヘルパーｔ細胞誘導性ポリペプチドの改変
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6163486B2 (ja) * 2012-07-02 2017-07-12 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
SG10201705028WA (en) 2012-12-17 2017-07-28 Otsuka Pharma Co Ltd Method for activating helper t cell
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
RS61173B1 (sr) 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
CN103961697A (zh) 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
KR102050931B1 (ko) * 2013-02-05 2019-12-02 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 테이프제
EP2762152A1 (de) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1-Peptidkrebsimpfstoffzusammensetzung zur transdermalen Verabreichung
EP2762157A1 (de) 2013-02-05 2014-08-06 Nitto Denko Corporation Impfstoffzusammensetzung zur transdermalen oder mukosalen Verabreichung
RU2687026C2 (ru) 2013-02-05 2019-05-06 Нитто Денко Корпорейшн Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения
CN103961306A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮给予用疫苗组合物
IN2014CH00396A (de) 2013-02-05 2015-04-03 Nitto Denko Corp
EP2974734B1 (de) 2013-03-12 2018-10-10 Sumitomo Dainippon Pharma Co., Ltd. Flüssige, wässrige zusammensetzung
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
SG11201507883SA (en) 2013-03-29 2015-10-29 Sumitomo Dainippon Pharma Co Ltd Wt1-antigen peptide conjugate vaccine
ES2841274T3 (es) 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
ES2916834T3 (es) 2014-09-27 2022-07-06 Sumitomo Pharma Co Ltd Composición farmacéutica para inyección
JP6947720B2 (ja) * 2015-09-10 2021-10-13 メモリアル スローン ケタリング キャンサー センター Ｔ細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法
SMT202200370T1 (it) 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
AU2017226956A1 (en) * 2016-03-03 2018-10-11 Institut Gustave Roussy PTPS-based vaccines against cancer
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
AU2019218397A1 (en) 2018-02-12 2020-10-01 Fred Hutchinson Cancer Center Cyclin A1 specific T cell receptors and uses thereof
JP7162675B2 (ja) 2018-09-28 2022-10-28 住友ファーマ株式会社 注射用組成物
CA3115240A1 (en) * 2018-10-05 2020-04-09 International Institute Of Cancer Immunology, Inc. Composition for preventing or treating benign tumor
TWI875736B (zh) 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
WO2020185796A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
JP7737978B2 (ja) 2019-08-20 2025-09-11 フレッド ハッチンソン キャンサー センター Ｗｔ－１に特異的なｔ細胞免疫療法
MX2022007905A (es) 2019-12-31 2022-08-25 Elixirgen Therapeutics Inc Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos.
WO2021231376A2 (en) * 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP7153287B2 (ja) 2020-05-12 2022-10-14 住友ファーマ株式会社 癌を処置するための医薬組成物
MX2024001843A (es) 2021-08-12 2024-05-16 Int Inst Cancer Immunology Inc Composición farmacéutica y método para tratar o prevenir cáncer.

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (ja) 1984-07-06 1986-01-30 Green Cross Corp:The 癌免疫療法増強剤
JP2546254B2 (ja) 1987-02-23 1996-10-23 澁谷工業株式会社 ガス詰め充填装置
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
JP3393867B2 (ja) 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
CA2069541C (en) * 1992-05-26 2005-02-01 Cornelis J. M. Melief Induction of an antigen-specific t-lymphocyte response
EP0741580A4 (de) 1993-12-14 2001-07-11 Univ Johns Hopkins Med Die kontrollierte freisetzung von pharmazeutisch aktiven substanzen in der immuntherapie
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
EP1167379A3 (de) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatorische Oligonukleotide
US6034235A (en) 1995-06-01 2000-03-07 Tadamitsu Kishimoto Growth inhibitor for leukemia cell comprising antisense oligonucleotide derivative to wilms tumor gene (WT1)
JP3904260B2 (ja) 1995-06-01 2007-04-11 岸本 忠三 ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
DE59611362D1 (de) 1995-09-19 2006-08-17 Bayer Bioscience Gmbh Pflanzen, die eine modifizierte stärke synthetisieren, verfahren zu ihrer herstellung sowie modifizierte stärke
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
JPH09191635A (ja) 1996-01-05 1997-07-22 Toshio Aida モータ
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US20030092656A1 (en) 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
JP4789095B2 (ja) 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
US5985264A (en) 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
AR021849A1 (es) 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030215458A1 (en) 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
CA2359110A1 (en) 1999-01-12 2000-07-20 Ronald James Boon Combination of hepatitis b vaccine with antiviral agents
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
EP1681064A1 (de) 1999-07-22 2006-07-19 Dainippon Sumitomo Pharma Co., Ltd. Induktion von antigen-spezifischen T-Zellen durch Interferon
JP2001089389A (ja) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
EP1371664B1 (de) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti-modifiziertes peptid
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JP5230891B2 (ja) 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的ｔ細胞の新規な誘導方法
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ES2331305T3 (es) * 2002-09-20 2009-12-29 International Institute Of Cancer Immunology, Inc. Peptidos de wt1 de tipo sustituido.
ES2332590T3 (es) * 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
WO2005001117A1 (ja) * 2003-06-27 2005-01-06 Haruo Sugiyama Ｗｔ１ワクチン適応患者の選択方法
KR101213015B1 (ko) 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
PT1731605E (pt) 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1

Also Published As

Publication number Publication date
KR20010072112A (ko) 2001-07-31
ES2318898T3 (es) 2009-05-01
EP2048160A1 (de) 2009-04-15
US20060093615A1 (en) 2006-05-04
CN100560130C (zh) 2009-11-18
KR100767554B1 (ko) 2007-10-17
BRPI9912663B8 (pt) 2021-07-06
EP1103564A1 (de) 2001-05-30
EP2280031B1 (de) 2015-04-15
US7608685B1 (en) 2009-10-27
HK1130069A1 (en) 2009-12-18
EP1103564A4 (de) 2005-02-02
HK1038929A1 (en) 2002-04-04
CA2337743A1 (en) 2000-02-10
BRPI9912663B1 (pt) 2011-05-31
JP5230579B2 (ja) 2013-07-10
US20160243209A1 (en) 2016-08-25
PT1103564E (pt) 2009-03-13
JP4422903B2 (ja) 2010-03-03
US20090281043A1 (en) 2009-11-12
CA2337743C (en) 2015-07-07
EP2048160B1 (de) 2015-01-07
HK1153761A1 (en) 2012-04-05
AU4932199A (en) 2000-02-21
CN1314916A (zh) 2001-09-26
US7030212B1 (en) 2006-04-18
HK1036073A1 (en) 2001-12-21
US20090143291A1 (en) 2009-06-04
US9403886B2 (en) 2016-08-02
CN1560078B (zh) 2011-06-22
JP2010059172A (ja) 2010-03-18
EP1103564B1 (de) 2009-01-07
CN1560078A (zh) 2005-01-05
US7807792B2 (en) 2010-10-05
CN1178956C (zh) 2004-12-08
US7390871B2 (en) 2008-06-24
EP2280031A1 (de) 2011-02-02
CN1762490A (zh) 2006-04-26
BRPI9912663A (pt) 2001-05-02
DE69940264D1 (de) 2009-02-26
US7517950B2 (en) 2009-04-14
US20050266014A1 (en) 2005-12-01
HK1038929B (zh) 2005-05-06
CN102198266A (zh) 2011-09-28
DK1103564T3 (da) 2009-05-11
WO2000006602A1 (fr) 2000-02-10

Similar Documents

Publication Publication Date Title
ATE420112T1 (de) Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
CY1113185T1 (el) Μεθοδοι συνενωσης αποδεκτη πεπτιδιου
CY1105919T1 (el) Αντιμικροβιακα πολυπεπτιδια απο pseudoplectania nigrella
DE69833649D1 (de) Ef-1-alpha transkriptionsregulatorische dna aus hamster
DK0586474T3 (da) Peptionukleinsyrer
AU4903101A (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
ATE375391T1 (de) Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
CY1108240T1 (el) ΑΠΟΜΟΝΩΜΕΝΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΤΑ ΟΠΟΙΑ ΕΧΟΥΝ ΕΝΑ ΜΕΙΩΜΕΝΟ ΠΕΡΙΕΧΟΜΕΝΟ ΜΟΤΙΒΩΝ 5΄CpG3΄ ΕΠΙΓΕΝΕΤΙΚΟΥ ΕΛΕΓΧΟΥ ΚΑΙ ΟΙ ΧΡΗΣΕΙΣ ΤΟΥΣ
TR199802648A3 (tr) Gen tedavisi için nüklein asit yapilari.
DK0817851T3 (da) DNA, der koder for humant papillomvirus type 18
DE69732029D1 (de) Dna enthaltende impfstoffen
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
FI970071A7 (fi) Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuum orihyljintäantigeeniä
CY1110850T1 (el) Μεθοδος για την ταυτοποιηση ενωσεων με σκοπο την θεραπεια διαδικασιων γηρανσης του καρδιαγγειακου συστηματος
EP2172214A3 (de) Chlamydia-Antigene und entsprechende DNA-Fragmente sowie Verwendungen davon
PT1005532E (pt) Moleculas de acido nucleico isoladas que codificam para membros da familia ssx e suas utilizacoes
DE69839765D1 (de) Lage-1 tumor-assozierte nukleinsäuren
WO2002083727A3 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
WO1998022586A3 (en) HUMAN POLYHOMEOTIC 2 (hph2) ACTS AS A TUMOR SUPPRESSOR
WO2001051518A3 (en) Nucleic acids encoding human semaphorin proteins and use thereof
CY1112454T1 (el) Ανασυνδυασμενη καρβοξυπεπτιδαση β
WO1998048045A3 (de) Verfahren zur nichtinvasiven erkennung bösartiger tumoren der lunge
ITVI940084A0 (it) Impilatore per prodotti laminari flessibili, particolarmente per pellied affini.
IT1277414B1 (it) Uso di macromolecole di tipo dendrimerico come catalizzatori o coadiuvanti delle reazioni in condizioni di trasferimento di fase
NO20011961D0 (no) PRV-1-genet og anvendelsen av dette

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1103564

Country of ref document: EP